U.S. markets open in 7 hours 15 minutes

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
29.93-0.41 (-1.35%)
At close: 04:00PM EDT
29.93 0.00 (0.00%)
After hours: 04:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close30.34
Bid11.92 x 1200
Ask47.68 x 900
Day's Range29.15 - 30.23
52 Week Range19.35 - 43.61
Avg. Volume367,616
Market Cap1.787B
Beta (5Y Monthly)0.60
PE Ratio (TTM)80.89
EPS (TTM)0.37
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
49% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for XNCR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xencor, Inc.
    XNCR: Raising target price to $28.00XENCOR INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Zacks

    Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

    Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Xencor Reports Second Quarter 2022 Financial Results

    MONROVIA, Calif., August 03, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2022 and provided a review of recent business and clinical highlights.

  • PR Newswire

    Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies

    Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced today a multi-year strategic option and license agreement to research, develop and commercialize XmAb® bispecific antibodies directed against nove